Logo

Bio-Thera Solutions Receives the NMPA’s Approval of BAT1806, a Biosimilar to Actemra

Share this
Bio-Thera Solutions

Bio-Thera Solutions Receives the NMPA’s Approval of BAT1806, a Biosimilar to Actemra

Shots:

  • The NMPA has approved BAT1806, a biosimilar of Actemra (tocilizumab) in China for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome
  • BAT1806 is highly similar to the reference drug in terms of quality, safety, and efficacy acc. to extensive analytical similarity, non-clinical similarity & clinical studies
  • The additional biosimilar products are being developed by the company, incl. proposed biosimilars for Simponi, Stelara, and Cosentyx, which are all undergoing in the P-III study, and a proposed biosimilar for Nucala in the P-I study. The US FDA & EMA has accepted the MAA of BAT1806/BIIB800

Ref: Businesswire | Image: Bio-Thera Solutions

Related News:- Bio-Thera Solutions Reports the NMPA's Acceptance of MAA for BAT1806 (biosimilar, tocilizumab) to Treat Rheumatoid Arthritis

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions